Publications by authors named "Alessandra Mecozzi"
Purpose: To date, litte evidence is reported about the real-life dosage of tyrosine kinase inhibitors prescribed in Italy. The present observational retrospective study aimed to evaluate the mean daily dose of nilotinib prescribed as first- and second-line therapy among patients suffering from chronic myeloid leukemia (CML) in settings of clinical practice in Italy.
Patients And Methods: Data were obtained from the administrative databases of a sample of Italian entities.
Article Synopsis
- Management of aTTP in patients who can't tolerate plasma is difficult, but new medications like rituximab and caplacizumab show promise.
- A 39-year-old woman with severe ADAMTS-13 deficiency faced anaphylaxis from plasma exchange, leading to the use of alternative treatments.
- This case highlights innovative strategies to monitor and improve patient care while managing resources during the COVID-19 pandemic.
Background: Management of chronic hepatitis C (CHC) has significantly accelerated in the last few years. Currently, second generation direct acting antivirals (DAAs) promise clearance of infection in most of patients. Here we present the results of the first analysis carried out on data of Lazio clinical network for DAAs.
View Article and Find Full Text PDFBackground: Current guidelines recommend prophylaxis with granulocyte colony-stimulating factors (G-CSFs) for patients with cancer who are at greater risk of febrile neutropenia (FN) while receiving chemotherapy. G-CSF biosimilars are available and represent a savings opportunity; however, their uptake has thus far been low.
Objective: Our objective was to evaluate prescribing patterns for G-CSFs in the prevention of chemotherapy-related FN and to evaluate the impact of regional guidance on G-CSF prescription.
Objectives: To evaluate the benefit/risk profile of epoetin α biosimilar with the erythropoiesis-stimulating agents (ESAs) originators when administered to naïve patients from clinical practice.
Design: Population-based observational cohort study.
Setting: All residents in the Lazio Region, Italy, with chronic kidney disease (CKD) or cancer retrieved from the Electronic Therapeutic Plan (ETP) Register for ESA between 2012 and 2014.